GFS202A for advanced solid tumors with weight loss
Part of Cancer clinical trials.
This study tests a new drug called GFS202A for people with advanced solid tumors who are experiencing weight loss or have a low body mass index (cachexia). The goal is to see if the drug is safe and can help improve appetite and weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor that is advanced (spread) and you are losing weight or have a low BMI (body mass index) under 21.
- You are between 18 and 80 years old.
- You have ongoing problems with appetite or eating due to your cancer.
- You are able to get around and take care of yourself (ECOG performance status 0-2).
- You do not have active brain metastases, uncontrolled infections, or serious heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational injection called INB301 to see if it can help reduce weight loss and improve appetite in people with cancer-related wasting (cachexia). It is a phase 1/2 study, so it is one of the first times the drug is given to people, and safety is a key goal.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
This study tests a new drug called DS010 to see if it can help people with cancer-related weight loss and muscle loss (cachexia). The goal is to improve appetite and strength, which may help you feel better during cancer treatment.
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
This trial tests a new drug, ASCA101, for people with certain cancers who are experiencing unwanted weight loss (cachexia). It aims to see if the drug can help improve appetite and stabilize weight. Participants must have colorectal, ovarian, or lung cancer and meet specific weight loss criteria.
This study tests whether a drug already approved for other cancers can help patients with advanced lung, pancreatic, or colorectal cancer who are losing weight. The drug may help improve appetite and weight stability.
Hear when a new Cancer Cachexia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.